Nguyen Ai-Lan, Horakova Dana, Havrdova Eva H, Barnett Michael, Sormani Maria Pia, De Stefano Nicola, Battaglini Marco, Vaneckova Manuela, Lui Elaine, Gaillard Frank, Desmond Patricia M, Prime Hayden, Datta Mineesh, van der Walt Anneke, Jokubaitis Vilija G, Podevyn Femke, Zivadinov Robert, Weinstock-Guttman Bianca, D'hooghe Marie B, Nagels Guy, Pesch Vincent Van, Laureys Guy, Van Hijfte Liesbeth, Lechner-Scott Jeannette, Patti Francesco, Cristiano Edgardo, Rojas Juan I, Sima Diana M, Van Hecke Wim, Kalincik Tomas, Butzkueven Helmut
Neuroimmunology Centre, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
CORe, Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
BMJ Neurol Open. 2025 Jul 22;7(2):e001126. doi: 10.1136/bmjno-2025-001126. eCollection 2025.
In a retrospective multicentre cohort study, we explored the association between brain atrophy and multiple sclerosis (MS) disability using different MRI scanners and protocols at multiple sites.
Relapse-onset MS patients were included if they had two clinical MRIs 12 months apart and ≥2 Expanded Disability Status Scale (EDSS) scores. Percentage brain volume change (PBVC), percentage grey matter change (PGMC), fluid-attenuated inversion recovery (FLAIR) lesion volume change, whole brain volume (BV), grey matter volume (GMV), FLAIR lesion volume and T1 hypointense lesion volume were assessed by icobrain. Disability was measured by EDSS scores and 6-month confirmed disability progression (CDP).
Of the 260 relapse-onset MS patients included, 204 (78%) MRI pairs were performed in the same scanner and 56 (22%) pairs were from different scanners. 93% of patients were on treatment and mean PBVC was -0.26% (±0.52). During the median follow-up of 2.8 years from the second MRI, median EDSS change was 0.0 and 12% patients experienced 6-month CDP. Cross-sectional BV and GMV at the later MRI showed a trend for association with CDP (HR 0.99; 95% CI 0.98 to 1.00; p=0.06). Only BV at the later MRI was associated with EDSS score (β -0.03, SE 0.01, p<0.001) and the rate of EDSS change over time (β -0.001, SE 0.0003, p=0.02). There was no association between longitudinal PBVC or PGMC and CDP or EDSS (p>0.05).
In this highly treated MS cohort with low disability accrual, only cross-sectional BV showed an association with future EDSS scores, while no MRI metric predicted 6-month CDP. These findings highlight the limitations of current clinical MRI measures in predicting disability worsening in real-world settings.
在一项回顾性多中心队列研究中,我们在多个地点使用不同的MRI扫描仪和方案,探讨脑萎缩与多发性硬化症(MS)残疾之间的关联。
纳入复发型MS患者,条件为他们在相隔12个月时有两次临床MRI检查,且扩展残疾状态量表(EDSS)评分≥2。通过icobrain评估脑体积变化百分比(PBVC)、灰质变化百分比(PGMC)、液体衰减反转恢复(FLAIR)病灶体积变化、全脑体积(BV)、灰质体积(GMV)、FLAIR病灶体积和T1低信号病灶体积。残疾程度通过EDSS评分和6个月确认的残疾进展(CDP)来衡量。
在纳入的260例复发型MS患者中,204例(78%)的MRI检查对在同一台扫描仪上进行,56例(22%)的检查对来自不同扫描仪。93%的患者正在接受治疗,平均PBVC为-0.26%(±0.52)。从第二次MRI开始的中位随访2.8年期间,EDSS的中位变化为0.0,12%的患者经历了6个月的CDP。后期MRI的横断面BV和GMV显示出与CDP相关的趋势(风险比0.99;95%置信区间0.98至1.00;p = 0.06)。仅后期MRI的BV与EDSS评分相关(β -0.03,标准误0.01,p < 0.